“The early proof-of-concept and safety data we’ve seen in this ongoing phase 1 study of ALKS 2680 in both healthy volunteers and four patients with narcolepsy type 1 are compelling. These data support further evaluation of ALKS 2680 as a potential treatm...
Alkermes(($ALKS))已发布更新。Alkermes宣布其食欲素激动剂计划取得重大进展,特别是其ALKS 26.